Compare ACET & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACET | DRIO |
|---|---|---|
| Founded | 1947 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 61.8M |
| IPO Year | 2017 | 2013 |
| Metric | ACET | DRIO |
|---|---|---|
| Price | $7.73 | $7.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $48.33 | $35.00 |
| AVG Volume (30 Days) | ★ 136.8K | 15.5K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1559.02 |
| EPS | N/A | ★ 10.12 |
| Revenue | N/A | ★ $7,394,000.00 |
| Revenue This Year | N/A | $20.27 |
| Revenue Next Year | N/A | $47.58 |
| P/E Ratio | ★ N/A | $0.73 |
| Revenue Growth | N/A | ★ 43.02 |
| 52 Week Low | $0.46 | $0.38 |
| 52 Week High | $9.05 | $17.74 |
| Indicator | ACET | DRIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 45.73 |
| Support Level | $6.28 | $7.37 |
| Resistance Level | $8.46 | $9.46 |
| Average True Range (ATR) | 0.47 | 0.46 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 57.30 | 69.85 |
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.